Literature DB >> 3928727

Amiodarone: risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study.

G V Naccarelli, N S Fineberg, D P Zipes, J J Heger, G Duncan, E N Prystowsky.   

Abstract

Ventricular tachycardia induced by programmed electrical stimulation during amiodarone therapy often does not preclude a good clinical response. The purpose of this study was to determine whether use of discriminant analysis could distinguish patients who remained asymptomatic from those who subsequently developed symptomatic ventricular tachycardia or cardiac arrest. Studies were performed in 37 patients with sustained ventricular tachycardia who still had ventricular tachycardia induced during programmed electrical stimulation during amiodarone therapy. The mean follow-up time was 14.1 +/- 1.3 months (+/- SEM). Twenty-three patients remained asymptomatic, whereas 14 patients had symptomatic recurrence of their ventricular tachycardia. In patients with recurrence of arrhythmia compared with asymptomatic patients, administration of amiodarone caused a longer ventricular effective refractory period (296 +/- 8 versus 271 +/- 7 ms, p less than 0.05) and a greater change in corrected QT [QTc] interval (90 +/- 18 versus 44 +/- 9 ms, p less than 0.02), but no difference in the decrease in premature ventricular complexes after treatment with amiodarone. During amiodarone therapy, nonbundle branch reentrant repetitive ventricular responses were induced by a single ventricular extrastimulus during sinus rhythm in 9 of 14 patients with recurrent arrhythmias compared with 2 of 21 asymptomatic patients (p = 0.001). Also, less aggressive pacing techniques were required to induce ventricular tachycardia in 9 of 14 symptomatic patients compared with 4 of 23 asymptomatic patients (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928727     DOI: 10.1016/s0735-1097(85)80488-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

Review 1.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 2.  Programmed stimulation in the evaluation of life-threatening or potentially life-threatening ventricular arrhythmias.

Authors:  C Gottlieb; M E Josephson
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

3.  Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction.

Authors:  L M Rodríguez; E B Sternick; J L Smeets; C Timmermans; K den Dulk; G Oreto; H J Wellens
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

4.  Electrophysiologic testing: predictive of amiodarone efficacy in recurrent sustained ventricular tachycardia?

Authors:  I J Mas; A Massumi; M Harlan; J J Seger; R J Hall
Journal:  Tex Heart Inst J       Date:  1987-12

5.  Out-of-hospital cardiac arrest in patients without clinically significant coronary artery disease: comparison of clinical, electrophysiological, and survival characteristics with those in similar patients who have clinically significant coronary artery disease.

Authors:  C J McLaran; B J Gersh; D D Sugrue; S C Hammill; A R Zinsmeister; D L Wood; D R Holmes; M J Osborn
Journal:  Br Heart J       Date:  1987-12

6.  Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction.

Authors:  A Proclemer; D Facchin; D Vanuzzo; G A Feruglio
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.